Free Webex Call
The Drug Eluting Stent Market was valued at USD 8.30 Billion in 2024, and is expected to reach USD 13.26 Billion by 2030, rising at a CAGR of 8.08%. Significant advancements within the global healthcare sector - particularly in technology and innovation - have played a critical role in enhancing patient care and treatment outcomes. Among these advancements, drug-eluting stents have emerged as a transformative solution in interventional cardiology. These small yet vital medical devices are revolutionizing the management of coronary artery disease (CAD), thereby fueling notable expansion in the global DES market. Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Drug-eluting stents are specialized medical devices used to treat coronary artery disease and reduce the likelihood of arterial re-narrowing. Comprising a metallic mesh tube coated with an anti-restenotic drug, DES function both as a structural support to maintain arterial patency and as a delivery system for controlled drug release. This dual function helps prevent restenosis following implantation in narrowed or blocked coronary arteries.
Key Market Drivers
Aging Global Population
The growing elderly population is a major driver of the DES market, as older individuals are more vulnerable to cardiovascular diseases, particularly CAD. With global life expectancy on the rise, demand for minimally invasive cardiac treatments is expected to increase. According to the World Health Organization, the global population aged 60 and above is expected to grow from 1 billion in 2020 to 1.4 billion by 2030 and reach 2.1 billion by 2050. The 80+ age group is also set to triple, rising to 426 million by 2050. This demographic shift has far-reaching implications for healthcare providers and device manufacturers, as cardiovascular treatments such as DES become increasingly essential.Key Market Challenges
Regulatory Hurdles
One of the primary challenges for the DES market is the constantly evolving regulatory landscape. Regulatory bodies across various regions frequently revise guidelines governing medical devices. As a result, manufacturers must allocate significant resources to ensure ongoing compliance. Securing approvals for new or modified products can be both time-intensive and costly, potentially delaying market entry and impacting profitability.Key Market Trends
Technological Advancements
Technological innovation is significantly reshaping the global healthcare landscape, with drug-eluting stents at the forefront of progress in interventional cardiology. One of the most notable advancements is the use of biocompatible polymers that optimize drug release kinetics and reduce adverse patient reactions such as inflammation or allergies.In addition, bioabsorbable stents represent a cutting-edge development. Designed to gradually dissolve within the body, these stents eliminate the long-term complications often associated with permanent metal implants, such as late-stage thrombosis. These innovations are expected to enhance treatment outcomes and further stimulate market growth in the coming years.
Key Market Players
- Abbott Laboratories ltd.
- Boston Scientific Corporation
- Terumo Corporation
- Medtronic plc
- Biosensors International Ltd
- Cook Medical pvt ltd.
- B. Braun Medical (India) Private Limited
- Biotronik, Inc.
- Lepu Medical Technology Inc.
Report Scope:
In this report, the Global Drug Eluting Stent Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:Drug Eluting Stent Market, By Coating Type:
- Polymer-based Coatings
- Polymer-free Coatings
Drug Eluting Stent Market, By Application:
- Coronary Artery Disease
- Peripheral Artery Disease
Drug Eluting Stent Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Drug Eluting Stent Market.Available Customizations:
With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.Company Information
- Detailed analysis and profiling of additional market players (up to five).
This product will be delivered within 1-3 business days.
Table of Contents
1. Product Overview
2. Research Methodology
3. Executive Summary
5. Drug Eluting Stent Market Outlook
6. North America Drug Eluting Stent Market Outlook
7. Europe Drug Eluting Stent Market Outlook
8. Asia-Pacific Drug Eluting Stent Market Outlook
9. South America Drug Eluting Stent Market Outlook
10. Middle East and Africa Drug Eluting Stent Market Outlook
11. Market Dynamics
12. Market Trends & Developments
14. Competitive Landscape
Companies Mentioned
- Abbott Laboratories ltd.
- Boston Scientific Corporation
- Terumo Corporation
- Medtronic plc
- Biosensors International Ltd
- Cook Medical pvt ltd.
- B. Braun Medical (India) Private Limited
- Biotronik, Inc.
- Lepu Medical Technology Inc
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 182 |
Published | April 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 8.3 Billion |
Forecasted Market Value ( USD | $ 13.26 Billion |
Compound Annual Growth Rate | 8.0% |
Regions Covered | Global |
No. of Companies Mentioned | 9 |